Get the Stockscreener App
0.89
2.24%
0.0195
Cytosorbents Corp stock is traded at $0.89, with a volume of 111.40K.
It is up +2.24% in the last 24 hours and down -25.21% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.8705
Open:
$0.917
24h Volume:
111.40K
Relative Volume:
1.19
Market Cap:
$47.38M
Revenue:
$31.09M
Net Income/Loss:
$-28.51M
P/E Ratio:
-1.4833
EPS:
-0.6
Net Cash Flow:
$-22.59M
1W Performance:
-12.75%
1M Performance:
-25.21%
6M Performance:
+1.14%
1Y Performance:
-37.32%
1-Day Range:
$0.86
$0.92
1-Week Range:
$0.86
$1.04
52-Week Range:
$0.70
$2.15
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Cytosorbents (CTSO) to Release Earnings on Thursday - MarketBeat
Cytosorbents (NASDAQ:CTSO) and Caliber Imaging & Diagnostics (OTCMKTS:LCDX) Critical Comparison - Defense World
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - MarketBeat
Analyst Scoreboard: 5 Ratings For CytoSorbents - Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts - Benzinga
FDA begins review of CytoSorbents' bleeding reduction device - Investing.com
FDA begins review of CytoSorbents' bleeding reduction device By Investing.com - Investing.com UK
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review - StockTitan
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results - StockTitan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - MarketBeat
Cytosorbents Co. (NASDAQ:CTSO) Short Interest Down 5.7% in September - MarketBeat
CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - MarketBeat
CytoSorbents maintains Buy rating from B.Riley with no change in target price - Investing.com
Cytosorbents announces $20 million "at the market" equity offering - Investing.com
Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits - Quantisnow
DrugSorb-ATR seeks FDA priority review for surgery bleeding - Investing.com
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update - The Manila Times
Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 81% loss from investing in the stock three years ago - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - MarketBeat
Stocks of Cytosorbents Corp (CTSO) are poised to climb above their peers - SETE News
Technical analysis of Cytosorbents Corp (CTSO) stock chart patterns - US Post News
Cytosorbents (NASDAQ:CTSO) Share Price Passes Above Two Hundred Day Moving Average of $0.94 - MarketBeat
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com - Defense World
CytoSorbents amends royalty agreement with ROKK LLC - Investing.com
CytoSorbents (STU:HQE1) Earnings Yield % : N/A% (As of Aug. 20, 2024) - GuruFocus.com
B. Riley Analysts Cut Earnings Estimates for Cytosorbents Co. (NASDAQ:CTSO) - MarketBeat
CTSO (CytoSorbents) Inventory-to-Revenue : 0.46 (As of Jun. 2024) - GuruFocus.com
CTSO (CytoSorbents) 3-Year EPS without NRI Growth Rate : -38.10% (As of Jun. 2024) - GuruFocus.com
HC Wainwright Reaffirms “Neutral” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits - Quantisnow
Cytosorbents Co. (NASDAQ:CTSO) Forecasted to Post Q3 2024 Earnings of ($0.05) Per Share - Defense World
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Analysts Offer Predictions for Cytosorbents Co.'s Q1 2025 Earnings (NASDAQ:CTSO) - MarketBeat
Cytosorbents Co. to Post Q1 2025 Earnings of ($0.02) Per Share, HC Wainwright Forecasts (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Announces Earnings Results, Beats Estimates By $0.01 EPS - Defense World
Cytosorbents Corporation (NASDAQ:CTSO) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: CytoSorbents sees growth and prepares for FDA submission - Investing.com
CytoSorbents: Q2 Earnings Snapshot - San Antonio Express-News
CytoSorbents names Peter Mariani as new CFO - Investing.com
StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results - Quantisnow
Cytosorbents (CTSO) to Release Quarterly Earnings on Tuesday - MarketBeat
Cytosorbents (CTSO) Set to Announce Earnings on Tuesday - Defense World
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results - Yahoo Finance
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):